Assessment of the potential of nebulised frusemide to relieve dyspnoea in people with advanced heart failure

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000096257

Enrollment

Registered

2009-02-11

Start date

2006-08-28

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Dyspnea is a burdensome symptom for individuals with heart failure (HF) and is responsible for high rates of hospitalization. Observational data, predominately in respiratory and cancer patients, suggest that nebulised furosemide may be useful for the symptomatic management of dyspnea. This evidence to date remains inconclusive and there have been no reports of the use of inhaled frusemide in HF. The aim of this study is to assess the impact of nebulised frusemide on the haemodynamic measures of heart function and on the symptom of dyspnoea in a population of patients with stable chronic heart failure

Interventions

Single dose administration of nebulised frusemide 40 mg (in 4 ml of diluent) to patients with chronic heart failure undergoing clinically-indicated right heart catheterisation. Frusemide/matching placebo is delivered as a single dose via a nebuliser immediately during right heart catheterisation immediately after completion of baseline haemodynamic measurements

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Chronic stable heart failure New York Heart Association Class 2-3

Exclusion criteria

Acute decompensated heart failure NYHA Class 1 or 4 Inability to provide informed consent

Outcome results